Lab #103

Assessment

Low Confidence

RecommendationSUPPLEMENT

Total Score3.05

Overall Assessment

This project scores 3.05/5.00 on the TRL 1 evaluation framework, reflecting a mixed but ultimately early-stage profile. The strongest dimension is therapeutic optionality (5/5, weighted 0.75), where the project demonstrates exceptional breadth across longevity, nootropics, and peptide therapeutics with 90+ structured hypothesis cards spanning dozens of validated biological targets and mechanisms. The therapeutic relevance score (3/5, weighted 1.80) reflects scientifically plausible mechanisms grounded in well-cited published literature, but is significantly moderated by the complete absence of any experimental validation — every single card has executionstatus=NOTRUN, and the sole computational campaign (EGFR A1) produced only 4 unvalidated in silico designs from 250 attempts with no measured binding affinity. The intellectual property score (2/5, weighted 0.50) is the weakest dimension: FTO status is universally UNKNOWN, no patents exist, most work involves well-known compounds and established targets, and the novel computational designs lack the experimental validation needed to establish defensible IP positions. The project's primary value lies in its systematic, well-structured identification of testable mechanistic gaps across a remarkably broad therapeutic landscape — essentially a comprehensive research roadmap. However, at TRL 1, the project remains entirely in the realm of concept and computational prediction, with $6.05 total spend and zero wet-lab data points. Advancement to TRL 2 would require executing at least some of the proposed assays to generate initial experimental evidence supporting the hypothesized mechanisms.

Weighted Score

Therapeutic Relevance

The project spans multiple scientifically plausible mechanisms across three lanes (longevity, nootropics, peptides) targeting biologically relevant disease mechanisms. The EGFR computational binder design (A1 campaign) targets a well-validated oncology target (UniProt P00533) with a clear EGF-competitive DI/DIII epitope strategy. The longevity hypothesis cards (L1–L32) address real mechanistic questions around rapamycin/mTORC2, senolysis/NAD/CD38, epigenetic clocks, and multiple geroprotectors (17α-E2, acarbose, spermidine, metformin, lithium, etc.) — all grounded in published literature with proper citations. The nootropics cards (N1–N32) systematically probe mechanism-of-action sufficiency for established compounds (modafinil, methylene blue, creatine, Lion's mane, nicotine, caffeine, etc.). The peptides cards (P1–P32) address BPC-157/FBXO22, FOXO4-DRI senolytic execution nodes, and numerous neuropeptide receptor-insufficiency hypotheses. However, the score is moderated because: (1) ALL work is purely computational or literature-based — zero experimental validation exists across the entire portfolio; (2) the EGFR campaign produced only 4/250 computational designs with no measured KD; (3) the vast majority of cards (~90+) are 'propose-assay' hypothesis cards with execution_status=NOT_RUN; (4) no binding data, cell-based assays, animal studies, or clinical evidence exist anywhere in the project. The mechanisms are scientifically plausible and well-referenced, but remain entirely unvalidated predictions at TRL 1.

Therapeutic Optionality

The project demonstrates exceptional therapeutic optionality and conceptual flexibility. It spans three distinct therapeutic lanes: (1) Longevity/aging — covering rapamycin mTORC2 tissue selectivity, senolysis-NAD-CD38 combinatorics, epigenetic clock validation, and mechanism-of-action sufficiency tests for 13+ geroprotectors (17α-E2, acarbose, spermidine, urolithin A, metformin, lithium, canagliflozin, resveratrol, melatonin, FGF21, taurine, αKG, BHB, lactate, succinate); (2) Nootropics/neuroscience — covering 18+ compounds/mechanisms (modafinil/DAT, methylene blue/MAO-vs-redox, creatine/PCr, Lion's mane/NGF, L-theanine, Rhodiola, Bacopa, nicotine, L-tyrosine, guanfacine, caffeine/A2A, atomoxetine, fluoxetine, rolipram, memantine, sarcosine, aniracetam, buspirone, baclofen); (3) Peptides — covering 18+ peptide/receptor systems (BPC-157/FBXO22/VEGFR2, thymosin β4/LKKTETQ, MOTS-c, humanin/MOMP, FOXO4-DRI execution nodes, SS-31/cardiolipin, ARA-290/IRR, Semax/TrkB, Selank/GABA, Dihexa/c-Met, oxytocin/OXTR, Exendin-4/GLP1R, ghrelin/GHSR, PACAP/PAC1, NPY/Y1, VIP/VPAC2, orexin/OX1R, CGRP/RAMP1, Substance P/NK1R, bradykinin/B2R). The EGFR computational design campaign adds an oncology dimension. This breadth across aging, neurodegeneration, cognitive enhancement, pain, inflammation, and oncology represents outstanding conceptual flexibility and multi-indication potential.

Intellectual Property

IP position is weak at this stage. The EGFR binder campaign (A1) uses well-known target (EGFR ECD, P00533) with established structural biology (PDB 8HGO/1IVO) and AI design engines (rfd3, boltzgen) — the computational designs are novel sequences but have no experimental validation, no measured binding, and no filed patents. The 4 passed designs (ipSAE_pred 0.557–0.717) are computational predictions only. FTO status is explicitly UNKNOWN across all hypothesis cards. No patents, patent applications, or freedom-to-operate analyses are mentioned anywhere in the project data. The vast majority of the work consists of literature-based hypothesis cards that propose experiments using well-known published compounds (rapamycin, metformin, BPC-157, methylene blue, etc.) and established genetic tools (various KO mice, siRNA, pharmacological antagonists) — these are assumption-kill/mechanism-dissection proposals rather than novel composition-of-matter or method claims. The 'subtract-before-add' and 'assumption-kill' experimental frameworks represent potentially novel experimental design IP (ip_class designations like 'subtract-before-add', 'redox-vs-MAO', 'momp-execution-gate', etc.), but these are conceptual frameworks, not protectable compositions. The BPC-157/FBXO22 mechanism (Zhang 2026 SPR KD=100nM) and the EGFR computational binders represent the strongest novel IP seeds, but both lack experimental validation. Risk of prior art is moderate-to-high given the well-studied nature of most targets.

Lab #103

Team

Project Score

Technology Readiness Level

Technology Readiness Level

Project Progress

Timeline

Timeline

Lab #103

Team

Project Score

Technology Readiness Level

Technology Readiness Level

Project Progress

Timeline

Timeline

Rationale

Assessment

Overall Assessment

Weighted Score